Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | hexokinase type 2 | 0.1073 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.0673 | 0.6204 | 0.6204 |
Loa Loa (eye worm) | hexokinase type II | 0.1073 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0732 | 0.6761 | 0.6728 |
Onchocerca volvulus | 0.1073 | 1 | 1 | |
Echinococcus granulosus | hexokinase | 0.1073 | 1 | 1 |
Onchocerca volvulus | 0.1073 | 1 | 1 | |
Entamoeba histolytica | hexokinase 2 | 0.1073 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.1073 | 1 | 1 |
Echinococcus multilocularis | hexokinase type 2 | 0.1073 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0341 | 0.3052 | 0.298 |
Trypanosoma cruzi | hexokinase, putative | 0.1073 | 1 | 1 |
Onchocerca volvulus | 0.1073 | 1 | 1 | |
Loa Loa (eye worm) | hexokinase | 0.1073 | 1 | 1 |
Leishmania major | hexokinase, putative | 0.1073 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.1073 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.1073 | 1 | 1 |
Plasmodium vivax | hexokinase, putative | 0.1073 | 1 | 1 |
Plasmodium falciparum | hexokinase | 0.1073 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.0102 | 0.0102 |
Trypanosoma brucei | hexokinase | 0.1073 | 1 | 1 |
Treponema pallidum | hexokinase (hxk) | 0.1073 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.1073 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0332 | 0.2965 | 0.2893 |
Leishmania major | hexokinase, putative | 0.1073 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.1073 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.1073 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0341 | 0.3052 | 0.298 |
Toxoplasma gondii | hexokinase | 0.1073 | 1 | 1 |
Brugia malayi | hexokinase type II | 0.0341 | 0.3052 | 0.3052 |
Echinococcus multilocularis | hexokinase | 0.1073 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.1073 | 1 | 1 |
Entamoeba histolytica | hexokinase 1 | 0.1073 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.0332 | 0.2965 | 0.2965 |
Loa Loa (eye worm) | hexokinase | 0.0673 | 0.6204 | 0.6165 |
Schistosoma mansoni | hexokinase | 0.1073 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.1073 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.1073 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.1095 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 23.7781 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.